Increasing the survival benefits from first‐line treatments in NSCLC patients with EGFR mutations and delaying the occurrence of resistance are two critical tasks that could be solved by EGFR‐TKI‐based combination therapies, including combinations with various chemo‐agents, targeted cancer drugs, and even immunotherapeutic methods. Here, EGFR is linked to cancer.